PCA
PRVB

Providence Capital Advisors’s Provention Bio, Inc. Common Stock PRVB Stock Holding History

Providence Capital Advisors’s Portfolio PRVB Stock Details PRVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-275
Closed -$2.91K – 345
2022
Q4 		$2.91K Hold
275
– – ﹤0.01% 239
2022
Q3 		$1K Hold
275
– – ﹤0.01% 314
2022
Q2 		$1K Hold
275
– – ﹤0.01% 286
2022
Q1 		$2K Hold
275
– – ﹤0.01% 399
2021
Q4 		$2K Hold
275
– – ﹤0.01% 317
2021
Q3 		$2K Hold
275
– – ﹤0.01% 284
2021
Q2 		$2K Hold
275
– – ﹤0.01% 291
2021
Q1 		$3K Buy
+275
New +$3.87K ﹤0.01% 252

Other funds holding PRVB

SC
Sessa Capital New York $5.51B AUM 47.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

Providence Capital Advisors's PRVB Position: Q1 2023 in Review

Providence Capital Advisors sold out of Provention Bio, Inc. Common Stock (PRVB) in Q1 2023, closing a stake of 275 shares — an estimated $2.91K sold.

Providence Capital Advisors first reported a position in PRVB in Q1 2021 and held it in 8 quarters. The position peaked at $3K in Q1 2021. 182 funds tracked by Wall St. Rank hold PRVB as of Q1 2023.

  • Providence Capital Advisors reported no remaining Provention Bio, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • Providence Capital Advisors sold 275 Provention Bio, Inc. Common Stock shares in Q1 2023, an estimated $2.91K.
  • Providence Capital Advisors first reported a position in Provention Bio, Inc. Common Stock in Q1 2021 and held it in 8 quarters.
  • Providence Capital Advisors's Provention Bio, Inc. Common Stock position peaked at $3K in Q1 2021.
  • 182 funds tracked by Wall St. Rank held Provention Bio, Inc. Common Stock as of Q1 2023.

Based on Providence Capital Advisors's 13F filing for Q1 2023, filed 10 May 2023.